The Philadelphia chromosome translocation generates a chimalternative splicing of the human CRK proto-oncogene. 8, 9 eric oncogene, BCR/ABL, which causes chronic myelogenous CRKL has the same overall organization as CRK II, consisting leukemia (CML). In primary leukemic neutrophils from patients of one N-terminal SH2 domain followed by two SH3 domains, lin. 5, 11, [15] [16] [17] [18] [19] Proteins which bind to bacterially expressed CRK bound to p210 BCR/ABL in CML cells, while CRKI and CRK II
protein, the focal adhesion protein paxillin, which is bound to CRKL, but not to CRKI or CRK II, in CML cells, and further showed that this interaction is specifically induced by the Introduction BCR/ABL oncogene. 5 Also, de Jong et al 21 recently demonstrated an interaction between CRKL and p120 CBL in The t(9;22) Philadelphia chromosome translocation generates BCR/ABL-positive cell lines, suggesting that CRKL could be a chimeric oncogene, BCR/ABL, which causes chronic myelinvolved in linking BCR/ABL to cellular signaling pathways. ogenous leukemia (CML). The BCR/ABL oncogene generates In contrast to CRK, there is still little known about the a fusion protein, p210 BCR/ABL , which is translocated to the involvement of CRKL in signaling pathways of either normal cytoskeleton and activated as a tyrosine kinase.
1-3 In cell lines or malignant cells. In an effort to compare in a more general either derived from patients with advanced phase CML or genmanner the interactions of CRKL and CRK II in normal and erated by transfection of the BCR/ABL oncogene, there are BCR/ABL transformed cells, we have generated monoclonal many cellular proteins which are constitutively tyrosine phosantibodies to CRKL, and used them to compare CRKL and CRK phorylated by p210 BCR/ABL , directly or indirectly, but the binding proteins in untransformed and BCR/ABL-transformed importance of these phosphoproteins for transformation is larhematopoietic cell lines. gely unknown. By contrast, in the early (stable) phase of the leukemia, there are only a few proteins which either interact with BCR/ABL or are phosphorylated by BCR/ABL. In earlier Materials and methods studies, we and others identified a 39 kDa tyrosine phosphoprotein complexed with BCR/ABL in CML stable phase neutroCell lines and culture phils to be the adapter protein, CRKL. [4] [5] [6] [7] . The CRKL protein has an overall amino acid homology of
The murine IL-3-dependent pro-B cell line, Ba/F3, was 60% to CRK II, one of the two products generated through obtained from Dr Alan D'Andrea (Dana-Farber Cancer Institute) and cultured in RPMI 1640 medium containing 10% fetal calf serum (FCS) and 10% WEHI-3B cell-conditioned Far Western blotting SH3(C), were obtained from Dr John Groffen (Children's Hospital, Los Angeles, CA) and generated as described preBa/F3 cells were incubated with or without rmIL-3 at 10 ng/ml for 5 min after starvation in RPMI 1640 with 0.5% bovine viously.
5 GST-CRK fusion proteins were obtained from Dr Bruce Mayer (Children's Hospital, Boston, MA, USA). To genserum albumin without WEHI-CM for 16 h. Unstimulated and IL-3-stimulated Ba/F3 and Ba/F3-p210 cells were lysed as erate anti-CRKL monoclonal antibodies, female Balb/c mice were immunized with a series of five biweekly subcutaneous described above and the lysates were subjected to immunoprecipitation using anti-CRKL mAb 5-6, anti-CRK antibody, or injections of purified GST-CRKL fusion protein (10 g per injection). Spleen cells of immunized mice and NS-1 myelpreimmune mouse serum. Immunoprecipitates were then subjected to SDS-PAGE and transferred to Immobilon PVDF oma cells were fused with polyethylene glycol, and hybridomas screened by enzyme-linked immunosorbent assay membranes as described above. The membranes were blocked with 5% non-fat dry milk in PBS-T (0.1% Tween 20 (ELISA) and immunoblot. Two monoclonal antibodies recognizing different epitopes were further characterized (mAb 2-2 in PBS, pH 7.4) and probed with GST-CRKL, GST-CRKL-SH2, GST-CRKL-SH3(N)-SH3(C), GST-CRK, GST-CRK-SH2, or GSTand mAb 5-6). Isotypes of antibodies were determined by class-specific anti-mouse immunoglobulin antibodies CRK-SH3(N) fusion proteins or GST protein (as a negative control) in binding buffer (1% non-fat dry milk, 25 mM Na (Amersham, Arlington Heights, IL, USA). Epitopes of antibodies were mapped by immunoblotting on GST-CRKL fusion PO 4 , pH 7.2, 150 mM NaCl, 0.1% Tween 20, 2.5 mM EDTA, 20 mM NaF, 1 mM dithiothreitol) with aprotinin (10 g/ml) proteins. Anti-CRK monoclonal antibody was obtained from Transduction Laboratories (Lexington, KY, USA). Anti-phosand leupeptin (10 g/ml) for 2 h. After washing with PBS-T, membranes were probed with anti-GST mAb (Santa Cruz photyrosine mAb, 4G10 25 was kindly provided by Dr Brian Druker (University of Oregon Health Sciences Center, PortBiotechnology, 1:500) for 1 h, washed again and further probed with HRP-coupled anti-mouse IgG antibody for 1 h, land, OR, USA). Anti-Abl mAb (Ab-3 clone) was purchased from Oncogene Science (Manhasset, NY, USA). Anti-Sos-1 washed again, and then subjected to the ECL chemiluminescence system. antibody for immunoblotting was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA), anti-Sos-1 antibody for immunoprecipitation was purchased from Transduction Laboratories, anti-C3G polyclonal Ab, and anti-p120 CBL polyResults clonal antibody were purchased from Santa Cruz Biotechnology. Normal mouse serum was used as a negative control Generation and characterization of specific monoclonal antibodies against CRKL antibody for immunoprecipitation experiments.
Two monoclonal antibodies against CRKL, 2-2 (IgG1) and 5-6 (IgG2a) were generated by immunizing mice with a GSTImmunoblotting and immunoprecipitations CRKL fusion protein. Partial epitope mapping using deletion mutants of CRKL fusion proteins revealed that mAb 2-2 recogCells were washed with ice cold phosphate-buffered saline, and were lysed in buffer containing 50 mM Tris (pH 8.0), 150 nizes an epitope in the N-terminal SH3 and mAb 5-6 recognizes an epitope in the C-terminal SH3 domain (data not mM NaCl, 1% NP-40 (w/v), 0.5% deoxycholic acid (w/v), 100 mM NaF, 1 mM phenylmethylsulfonyl fluoride, 20 g/ml shown). CRKL expression was examined in various cell lines by immunoblot (Figure 1 shows results using mAb 5-6, and aprotinin, 1 mM sodium orthovanadate, and 40 g/ml leupeptin at 10 8 cells/ml. After incubation on ice for 20 min, cell the same result was obtained using mAb 2-2 (data not shown)). CRKL was detected in all cell lines examined includlysates were centrifuged at 12 000 g for 15 min. The resulting supernatants were subjected to immunoprecipitation or ing nonhematopoietic cell lines (NIH3T3, Hepa, HepG2 and Cos), T cell lines (CTLL, Jurkat and H9), B cell lines (Ba/F3, immunoblotting directly as whole cell lysates. For immunoprecipitation, cell lysates were incubated with anti-CRKL antiDaudi and Ramos), a monocytic line (U937) and myeloid cell lines (32D, HL-60, MO7e, TF-1, K562 and BV173). In other bodies (2-2 or 5-6), anti-CRK antibody or preimmune mouse serum and protein A sepharose (for mAb 5-6 or preimmune studies, both mAbs were found to recognize human, murine and monkey CRKL, but did not react with CRK II proteins from mouse serum) or protein G sepharose (for mAb 2-2) for 3 h at 4°C. After incubation, supernatants were saved as immunothese species (data not shown).
In studies not shown, CRK II expression was readily detected, as expected, by Western blot in all the cell lines described above using a commercially available monoclonal antibody. Also, both anti-CRKL and anti-CRK antibodies were found to precipitate Ͼ75% of the cellular CRKL or CRK, respectively, in a single precipitation. 3). The 70 kDa protein bound more to CRKL than CRK, while We also observed that virtually no tyrosine phosphoproteins the 60 kDa protein bound more to CRK than CRKL. The coprecipitated with CRKL under the conditions employed here 70 kDa protein bound through an SH3 domain interaction, in cell lines not transformed by BCR/ABL or in untransformed, while the 60 kDa protein bound through an SH2 domain quiescent, cells.
interaction (data not shown). CRK II has previously been shown to be widely expressed. 
CRK-and CRKL-SH3 binding proteins
To determine which of these proteins bind to the SH3 domains of CRKL, we performed far Western blotting using a GST-CRKL-SH3(N)-SH3(C) fusion protein as a direct probe. As shown in Figure 5 , it was found that most of the proteins forming a broad 140-170 kDa band detected in both Ba/F3 and Ba/F3-p210 cells were CRKL SH3-binding proteins. In addition to these proteins, a single protein around 70 kDa detected only in untransformed Ba/F3 cells and a single protein around 210 kDa detected only in Ba/F-p210 cells were found to be CRKL-SH3-binding proteins. No proteins were detected with a CRK SH3 probe which could be identified by far Western blotting with GST-CRK-SH3 ( Figure 5 ).
CRK-and CRKL-SH2 binding proteins
The same procedure was performed using a GST-CRKL-SH2 fusion protein as a direct probe. Two proteins around 105-120 kDa detected only in Ba/F3-p210 cells were identified as CRKL SH2-binding proteins ( Figure 6 ). In untransformed Ba/F3 The experiment shown in Figure 3 indicates that both CRK and CRKL can potentially bind effectively to an overlapping Previous studies have identified c-ABL, C3G and SOS as cellular proteins which can interact with c-CRK and possibly, set of cellular proteins. However, in vitro binding does not necessarily reflect in vivo binding. To assess in vivo interac-CRKL. 5, 11, [15] [16] [17] [18] [19] 22 Since the molecular weights of the proteins identified by far Western blot as CRKL binding proteins were tions of CRK and CRKL, we performed far Western blotting in which anti-CRKL (mAb 5-6) or anti-CRK immunoprecipitates consistent with SOS, C3G and ABL, these proteins were examined directly in anti-CRKL immune complexes with specific were subjected to direct detection by GST-CRKL or GST-CRK II fusion proteins, respectively (as described in Materials and antibodies ( Figure 7) . SOS, C3G and c-ABL proteins are contained within the 140-170 protein complex detected by methods). This technique has the advantage that it is semiquantitative and that it only detects proteins which both CRKL-SH3. The p210 band was shown by anti-ABL blotting to be p210 BCR/ABL . Interestingly, the binding of SOS, C3G and coprecipitate with CRKL or CRK and also bind directly to CRKL or CRK, respectively. Anti-CRKL immunoprecipitates c-ABL proteins with CRKL is constitutive and is not changed following BCR/ABL transformation. Also, after transformation, were found to contain several cellular proteins in both untransformed and BCR/ABL-transformed Ba/F3 cells when c-ABL is not displaced by BCR/ABL, as about the same amount of c-ABL and BCR/ABL are precipitated. Thus, considering probed with GST-CRKL, while a GST probe was negative (Figure 4) . In untransformed cells, the most prominent CRKL also the data shown in Figure 3 , and consistent with previous studies, CRK can apparently bind through its SH3 domains to binding proteins detected were p140-170 and p70. In BCR/ABL-transformed cells, the pattern was similar except that c-ABL, C3G and SOS, the amount of these proteins actually coprecipitating with CRK is significantly less than that with the p70 protein was diminished, and proteins migrating at approximately 210 kDa and 105-120 kDa were also detected.
CRKL in the cell lines examined. This also includes BCR/ABL, thus presumably explaining the observation that CRKL, but not No prominent proteins which are smaller than 50 kDa were detected, suggesting that CRKL might not bind to itself, at least CRK, is an in vivo substrate of BCR/ABL. To confirm the apparent quantitative difference between in an inter-molecular manner. In contrast, anti-CRK precipitates did not contain detectable CRK-binding proteins in CRKL-and CRK-binding proteins in Ba/F3 cells, we performed the reverse immunoprecipitations, immunoprecipitations with untransformed cells, although a prominent 120 kDa protein was detected in BCR/ABL-transformed cells (Figure 4) . Both anti-C3G, ABL or SOS; followed by immunoblotting with anti-CRK or anti-CRKL. CRKL was detected in C3G, ABL, and SOS anti-CRKL and anti-CRK antibodies effectively precipitated 
Figure 5
Detection of CRK-and CRKL-binding proteins using CRK-SH3 and CRKL-SH3 fusion proteins as probes. The membranes Figure 6 Detection of CRK-and CRKL-binding proteins using used were prepared as described in the legend for Figure 4 using anti-CRK-SH2 and CRKL-SH2 fusion proteins as probes. The membranes CRK and anti-CRKL immune complexes. Proteins on the membranes used were prepared as described in the legend for Figure 4 . The prowere probed with GST-CRK-SH3(N) or GST-CRKL-SH3(N)-SH3(C) teins on the membranes were probed with GST-CRK-SH2 or GSTfusion proteins. The heavy band at about 55 kDa represents the CRKL-SH2 fusion proteins. The heavy band at about 55 kDa repimmunoglobulin heavy chain of the antibody used for immunoprecipresents the immunoglobulin heavy chain of the antibody used for itation.
immunoprecipitation.
Figure 7
Identification of major CRKL-SH3-binding proteins. The membranes used for far Western blotting were stripped and reprobed with specific antibodies against c-ABL, SOS or C3G. The heavy band at about 55 kDa represents the immunoglobulin heavy chain of the antibody used for immunoprecipitation.
immunoprecipitates, while CRK was not (Figure 8 ). The presp120 CBL antibody (Figure 9 ), consistent with the observations of de Jong 21 , Ribon 27 and our previous studies. 22 This result ence of BCR/ABL did not affect the amount of CRKL detected, except for anti-ABL immunoprecipitates. These results are suggests that CRKL could form complexes in vivo that link c-ABL, BCR/ABL, or guanine nucleotide exchange factors, such consistent with the notion that CRKL is a more abundant binding partner than CRK for C3G, c-ABL and SOS.
as C3G and SOS, with a protooncoprotein, p120 CBL , in BCR/ABL-transformed cells. The effects of this complex on It is interesting that a 70 kDa CRKL-SH3-binding protein was detected only in untransformed Ba/F3 cells, and disaptransformation will be interesting to study. CRK may also form such complexes, 27 but our data suggest that CRKL is quantitatpears after BCR/ABL transformation. A 70 kDa protein also binds to CRKL-SH3 in another murine hematopoietic cell line, ively more important. Overall, these observations suggest a mechanism to explain the observations by our group and 32D, and is again diminished dramatically in BCR/ABL-transformed 32D cells (data not shown). The identity of this protein others that p120 CBL is a prominent target of BCR/ABL both in cell lines and in primary leukemic cells from patients with is currently unknown.
CML.
The major CRK-SH2 and CRKL-SH2-binding protein is p120
CBL

Discussion
BCR/ABL is a tyrosine kinase oncogene which transforms One of the 120 kDa proteins detected by CRKL-SH2 and CRK-SH2 in BCR/ABL-transformed cells was identified as p120 CBL , hematopoietic cells in vivo and in vitro, but does not effectively transform many non-hematopoietic cell lines. 28 The by probing anti-CRKL immunoprecipitates with an anti- immunoprecipitates were probed with GST-CRKL (full length), a complex of CRKL-coprecipitating proteins from 140-170 kDa were the major proteins detected in non-transformed hematopoietic cells. In the same cell line transformed by BCR/ABL, the 140-170 kDa complex was detected as well as a 210 kDa protein and proteins at 105-120 kDa. Using GST-CRKL-SH2 and -SH3 domain fusion proteins as probes, the 140-170 kDa series of proteins in both untransformed and transformed cells and the 210 kDa protein were found to bind directly to the SH3 domain of CRKL, but not the CRKL SH2 domain. In contrast, the 105-120 kDa proteins observed only in BCR/ABL-transformed cells bound only to the CRKL SH2 domain. These data suggest that in untransformed cells, CRKL is in a complex with several proteins through its SH3 domain(s), but that its SH2 domain is largely uncomplexed in quiescent cells. It will be of interest to determine if the CRKL SH2 domain can be induced to bind to cellular proteins following activation by integrin crosslinking, adhesion, or stimulation by other growth factors or cytokines.
Interestingly, when these studies were repeated with anti-CRK monoclonal antibodies, CRKL and CRK II were found to be quantitatively different in terms of association with cellular proteins in both untransformed and BCR/ABL-transformed Ba/F3 cells, although quite similar when tested by direct far Western analysis of total cellular proteins. While proteins coprecipitating with CRKL through interactions mediated by the CRKL SH3 domains were readily identified, proteins were difficult to detect in anti-CRK immunoprecipitates. This was not due to failure to adequately immunoprecipitate CRK II, failure of the GST-CRK II fusion proteins to function as probes in far Western blots, or competition between the anti-CRK antibody and cellular proteins for binding to the same site on CRK II. It is quite possible that small amounts of proteins are bound to the CRK II SH3 domains, below the limit of detection of the technique used here. In fact, in other cell systems, binding of CRK II to cellular proteins such as C3G, SOS and c-ABL has been readily demonstrated. 11, 13, 15, 20, 27, [34] [35] [36] [37] [38] None the
Figure 9
Identification of the major CRKL-SH2-binding protein.
less, the available data suggest that there is at least a quantitat-
The membranes used for far Western blotting were stripped and reprobed with a specific antibody against p120 CBL .
ive difference between CRKL and CRK II in binding to proteins through the SH3 domains in these hematopoietic cell lines. Previous studies with CRK II have suggested that the SH2 domain binds intramolecularly to the ptyr-X-X-pro motif conchimeric oncoprotein p210 BCR/ABL is known to bind the actin cytoskeleton through a conserved C-terminal domain in c-ABL taining the major tyrosine phosphorylation site at tyr 221 . 11 This would block interaction of the SH2 domain with cellular proand this interaction is believed to be important for transformation.
2,3 It has been suggested that p210 BCR/ABL recruits sigteins and could also interfere with access to the SH3 domains. However, in both the untransformed and BCR/ABL-transnaling proteins which ultimately affect adhesion, proliferation and viability. [29] [30] [31] [32] [33] In the stable phase of the disease, the tyroformed cell lines tested here, CRK was not detectably tyrosine phosphorylated, and it is therefore not likely that intramolecusine kinase activity of BCR/ABL is apparently lower than during the blast phase, and increased tyrosine phosphorylation is lar binding of CRK SH2 is the explanation for the relatively reduced amount of CRK SH3 binding proteins. The possibility detectable on only a few cellular proteins. One of these proteins, CRKL, is phosphorylated in leukemic cells from patients that the CRKL SH2 can undergo any type of intramolecular binding has not been assessed. We did not observe direct both early and late in their course, and has been shown to physically interact with BCR/ABL through its SH3 binding in vitro of CRKL-SH2 to phosphoCRKL when anti-CRKL immune complexes were probed with a GST-CRKL-SH2 domains. 4, 6, 7, 21 The SH2 and SH3 domains of CRKL are related to CRK II, fusion protein in a far Western blot, although this does not prove that intramolecular binding does not occur in vivo. and in vitro binding studies suggest that the two adapter proteins bind to a highly overlapping set of proteins. However,
The immunoprecipitation/far Western assay used is semiquantitative since the fusion protein probes are used in excess in vivo, CRK II and CRKL may or may not have related functions. In the studies reported here, we have carefully comduring the direct binding assay. However, if there are multiple SH2-binding sites on a protein, the assay would overestimate pared the protein interactions of CRKL and CRK in a hematopoietic cell line, both untransformed and transformed by the abundance of that protein relative to others in the immune complex. It is likely that a fraction of the CRKL molecules are BCR/ABL.
Specifically, we used a combination of immunoprecipitinvolved in a small number of protein complexes in quiescent, untransformed cells, and that several novel protein complexes ation and far Western blotting to examine CRKL-and CRKassociated proteins. When anti-CRKL monoclonal antibody are formed after transformation. In untransformed cells, CRKL is complexed through its SH3 domains to a group of proteins phorylated on tyrosine residues in cells transformed by activated ABL oncogenes, and also that p120 CBL and BCR/ABL which include C3G, SOS and c-ABL. 11, 20, 36 It is not possible to compare precisely the relative amounts of these three proform a complex. C3G and SOS were examined in this study because of the sine kinases activated after cytokine receptor stimulation.
52,53
Also, we have recently shown that p120 CBL is tyrosine phosobserved molecular weights of the CRKL binding proteins and because of previous studies identifying possible CRK binding phorylated in hematopoietic cells in response to integrin crosslinking. 54 The downstream signaling pathways are proteins. C3G was originally identified as a protein which could bind to the SH3 domain of CRK, and the binding site unknown, but p120 CBL is physically associated with the p85 subunit of phosphoinositol-3-kinase in both activated normal for the first CRK II SH3 domain was identified as a proline-rich sequence in C3G containing an important lysine residue.
38,39 cells 55, 56 and in BCR/ABL-transformed cells. 22 The function of c-Cbl is unknown, however. A homologue of c-Cbl in C. eleSequence analysis of C3G suggested it was a guanine nucleotide exchange factor, and subsequent studies confirmed that gans, Sli-1, is a negative regulator of tyrosine kinase signaling.
57
C3G had exchange factor activity in vitro for the small GTP binding protein, Rap1, but not for p21 ras . 40 SOS is a well The results presented here confirm that CRKL functions as a linker protein in CML cells. 6, 7, 21 At the present time, the known guanine nucleotide exchange factor with in vitro activity for p21 ras . SOS has been linked to the control of p21 ras role of CRKL-containing complexes in transformation remains speculative. The fact that several of the proteins identified function in signaling pathways activated by several growth factor receptors, typically through binding to the two SH3 are known to play a role in integrin signaling is of interest, since significant adhesion defects in CML progenitor cells domains of GRB2. It is not yet known if the binding sites for the SH3 domain of CRKL overlap with the binding sites for have been described by Verfaillie, Gordon, and our own groups. [58] [59] [60] Further studies will be necessary to determine if the SH3 domains of GRB2. It is possible, however, that SOS can be linked to different cellular proteins through GRB2 and these interactions lead to aberrant adhesive properties or other biological effects. Overall, we suggest that the interaction CRKL. It is also possible that individual SOS molecules bind both GRB2 and CRKL and that the resulting complexes conof BCR/ABL with p120 CBL through CRKL, but not CRK, could contribute to the known signaling abnormalities which tain other proteins depending on the pattern of tyrosine phosphorylation. There is abundant evidence that BCR/ABL can cause CML. activate the p21 ras pathway, 25, [41] [42] [43] [44] [45] and several investigators feel that this is an important pathway for transformation. Thus, the data presented here suggest that in addition to a direct link Acknowledgements to SOS through binding of GRB2 to tyr 177 of BCR/ABL, 46 binding of CRKL to SOS could also affect SOS function. In contrast This work was supported by NIH grants CA36167 (JDG) and to GRB2, there are no data suggesting that CRKL directly links CA60821 (RS). BCR/ABL to SOS, since both BCR/ABL and SOS interact with the CRKL SH3 domains.
The interaction of CRKL with c-ABL in both untransformed References and transformed cells is of considerable interest. Our data suggest that this association is constitutive, and not further part of the response to DNA damage induced by radiation. 47 transformation by the Bcr-Abl oncoprotein of Philadelphia chroc-ABL is thought to be predominantly nuclear, while our stud- Cbl. 49, 50 The CAS NS-1 retrovirus induces pre-B cell lym- Andoniou and colleagues 51 reported that p120 CBL is phos-
